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Abstract. 
Abstract: The goal of re-programming the host immune system to target malignancy with durable anti-
tumour clinical responses has been speculated for decades. In the last decade such speculation has 
been transformed into reality with unprecedented and durable responses to immune checkpoint 
inhibitors seen in solid tumours. This mini-review considers the mechanism of action of immune 
modulating agents and the potential for combination with radiotherapy in the treatment of non-small 
cell lung cancer.  
 
  
Introduction. 
The goal of re-programming the host immune system to target malignancy with durable anti-tumour 
clinical responses has been speculated for decades [1]. However only over the last decade, has the 
use of immune modulating agents delivered meaningful clinical responses that has led to great 
promise in the treatment of lung cancer as well as other solid malignancies [2]. This mini-review 
outlines the mechanism of action of immune modulating agents and the potential for combination 
with radiotherapy in the treatment of non-small cell lung cancer (NSCLC). 
 
Immunotherapy in Lung Cancer. 
Immunotherapeutic strategies can be broadly considered as either passive or active. Passive 
approaches delivered the initial major clinical advances with the introduction of the anti-CD20 
monoclonal antibody (mAb) Rituximab which was the first mAb licensed in the treatment of cancer in 
1997 followed closely by Trastuzumab with targets and binds to the extra-cellular domain of the HER-
2/neu receptor which interferes with receptor function and expression [2,3]. Active immunotherapy 
approaches include non-specific immune modulation (use of interleukin and interferon), therapeutic 
vaccines (e.g. MAGE-A3 vaccine), modulation of T-cell function and oncolytic viruses and have been 
slower to demonstrate clinical efficacy [4-6]. However, it is the modulation of T-cell function with the 
immune checkpoint inhibitors which modulate the anti-CTL antigen-4 (CTLA-4) and the anti-
programmed death-1 (PD-1) ligand function which has particularly attracted interest over the last 5 
years with durable clinical responses being seen in malignant melanoma, renal cell carcinoma and 
non-small cell lung cancer, amongst other tumour types [7].  
 
For many years it has been known that tumours can evade and  escape the immune system by a range 
of immune effectors cells such as T regulatory cells, myeloid deprived suppressor cells (MDSC), tumour 
associated macrophages (TAM) and via the production of a range of immunosuppressive cytokines 
(e.g.  IL-10, TGF-beta, PGE2 and interferon-ƴ (IFN-ƴ)) within the tumour microenvironment which lead 
to suboptimal priming of dendritic cells and a tolerogenic phenotype [8-10]. A key mechanism of 
immune evasion is known to be the direct inhibition of cytotoxic T-cells. T-cell activation is a two-step 
process with the first being antigen recognition by the T-cell receptor and the second the generation 
of an antigen-independent co-regulatory signal that determines whether the T-cell will be switched 
on or off in response to the antigen. This second step is overseen by the immune checkpoint pathways, 
which are either stimulatory or inhibitory. More recently these biological insights about the nature of 
immune checkpoint inhibitors have led to an increasing number of therapeutics with an intense focus 
on the PD-1-PD-L1 axis (Programmed Death 1). PD-1 is an inhibitory receptor expressed on T-cells is 
key to preventing the development of autoimmune disease and it is thought that the function of PD-
1 is to limit normal tissue damage in the presence of inflammation [11,12]. PD-L1 and PD-L2 are ligands 
of PD-1 (PD-L1 and PD-L2) and these bind to PD-1 to inhibit T-cell function. Upregulation of PD-L1 and 
PD-L2 is common in many tumour types and is associated with a poorer prognosis [13]. A number of 
PD-L1 and PD-L2 inhibitors have been shown to be effective across a range of tumour sites [14]. Two 
agents, Pembrolizumab and Nivolumab have been shown in randomised trials to be superior to 
chemotherapy in the second line treatment of NSCLC [15-17]. In a randomised study comparing 
Docetaxol versus Pembrolizumab as second line therapy in patients with advanced NSCLC who 
expressed PD-1, those who received Pembrolizumab 10 mg/kg had median overall survival of 17.3 
months as compared to 8.2 months with docetaxel (p<0·0001) [15]. Similarly in a study comparing 
Nivolumab versus Docetaxel in second line non-squamous NSCLC, those who received Nivolumab had 
a 1 year survival of 19 months compared to 8 months for those received in Docetaxol [17]. Also, 
importantly in the setting of second line treatment for NSCLC, this increase in survival did not come at 
the expense of increased toxicity in these studies. For example in the study of Nivolumab versus 
docetaxel in non-squamous NSCLC, treatment-related adverse events of grade 3 or 4 were seen in 
10% of those treated with Nivolumab, as compared with 54% of those treated with docetaxel [17].  
The results from checkpoint inhibition in NSCLC has led to the hope that these agents may improve 
outcomes in a range of different treatment indications and in early as well as late stage NSCLC. 
 The potential of Radiotherapy with immunotherapy combinations. 
Despite the excitement of durable remissions seen in the three key studies of using immune check-
point inhibitors in lung cancer, the response rates were low (18-20%) with only a minority of patients 
achieving a response [15-17]. The key focus in radiobiology over the last decades has been the 
mechanism of radiotherapy-induced tumour cell death and research on radiation induced damage to 
cell structures mediated by free-radicals, leading to the production of DNA double-strand breaks, 
which in turn lead to apoptosis, if not repaired [18-20]. However as our understanding of the effects 
of RT has increased it has been recognised that radiation has effects on the vascular system, the 
tumour stroma and the host immune response. The impact that RT is known to have on the generation 
of tumour-specific immunity, includes enhanced antigen release, expression of NK2GD ligands, 
complement deposition, production of type I IFN, Increased major histocompatibility complex (MHC) 
and neo-antigen expression and the induction of immunogenic cell death [21-25]. Other elements of 
immunogenic modulation include changes in the mechanism of antigen presentation and 
translocation of calreticulin to the cell surface [26-27]. Thus RT may act as a primer for or stimulus to 
initiate or augment an immune mediated anti-tumour response.  
Despite the ability of RT to induce local immune responses, the generation of systemic anti-tumour 
immunity that leads to clinical responses outside of the irradiated tumour area (the abscopal effect) 
is rare in clinical practice [28]. This lack of abscopal effects is thought to be secondary to the nature of 
the immuno-suppressive tumour microenvironment outlined above. Numerous preclinical studies 
have however confirmed that systemic anti-tumour immune responses can be generated using RT and 
immunomodulatory agents [7].   
Recently there has been increasing interest in the translation of these findings to the clinic which has 
been fuelled by a number of provocative case reports and Phase II studies [29-32]. Overall these 
results suggest RT after immunoregulatory agents may lead to abscopal responses in some patients 
providing optimism that RT can enhance the systemic anti-immune response. The premise is that RT 
delivered to the tumour appears able to enhance anti-tumour immunity by inducing tumour antigen 
expression and liberating tumour antigen from dying tumour cells and thus activating anti-tumour 
immune responses. These local RT induced immune responses however need to be augmented with 
the addition of immune checkpoint inhibitors which increase enhance the local and systemic immune 
response by overcoming the tumour induced T-cell inhibition and immune suppression [33]. Thus 
combining RT with inhibitors of PD-1 or the ligand of PD-1 (PD-L1) appears to be an attractive option 
to enhance the effectiveness of either treatment [34]. Given the durable remissions seen with anti-
PD-1 / PD-L1 mAb for some patients with NSCLC and important role played by RT in the management 
of NSCLC it is logical to try and increase response rates and improve outcome by combination 
approaches.  
 
  
Table 1: Studies of Pembrolizumab or Nivolumab in combination with radiotherapy in NSCLC. 
Study Name / 
NCT number 
Study intervention Phase Host institution Status 
PEMBRO-RT35 Pembrolizumab after 
SABR Versus 
Pembrolizumab Alone in 
Advanced NSCLC 
Randomised 
Phase 2 
Netherlands 
Cancer Institute, 
Amsterdam 
Open, 
recruiting 
NCT0244474136 Dose escalation study of 
Pembrolizumab and 
SABR in stage IV NSCLC 
Phase 1 / Phase 
2 
M.D. Anderson 
Cancer Center, 
Houston, Texas 
Open, 
recruiting 
PEAR Study37 Pembrolizumab and 
Palliative Radiotherapy 
in Lung 
Phase 1 Royal Marsden 
Hospital, 
London 
In set-up. 
NCT0234395238 Previous Study | Return 
to List | Next Study 
Consolidation 
Pembrolizumab 
Following 
Chemoradiation in 
Patients With 
Inoperable/Unresectable 
Stage III NSCLC 
Phase 1 Hoosier Cancer 
Research 
Network, USA 
Open, 
recruiting 
NCT0262139839 Pembrolizumab, 
Paclitaxel, Carboplatin, 
and Radiation Therapy in 
Treating Patients With 
Stage II-IIIB Non-Small 
Cell Lung Cancer 
Phase 1 Rutgers Cancer 
Institute of New 
Jersey and the 
National Cancer 
Institute (NCI) 
 
Open, 
recruiting 
NCT0260838540 Study of PD1 Blockade 
by Pembrolizumab With 
Stereotactic Body 
Radiotherapy in 
Advanced Solid Tumors 
Phase 1 University of 
Chicago 
Open, 
recruiting 
NCT0240717141 Evaluating the 
Combination of MK-
3475 and Sterotactic 
Body Radiotherapy in 
Patients With Metastatic 
Melanoma or NSCLC 
Phase 1/I2 Yale University Open, 
recruiting 
NICOLAS42 NIvolumab 
COnsolidation After 
Standard First-line 
Chemotherapy and 
Radiotherapy in Locally 
Advanced Stage IIIA/B 
NSCLC (NICOLAS) 
Phase  2 European 
Thoracic 
Oncology 
Platform 
Open, 
recruiting 
 
 
Potential Radiotherapy and Immunotherapy Combinations in Non-Small Cell Lung Cancer. 
Advanced metastatic disease provides an opportunity to investigate whether radiotherapy-
immunotherapy combinations may lead to abscopal responses [34]. However, the dose, fractionation 
and optimal delivery of radiotherapy such as SABR delivering large hypofractionated doses remains 
unclear. Radiotherapy doses from 2 Gy but up to 20 Gy may be sufficient to trigger an immune 
mediated cell death and large doses may increase the tumour cell kill and subsequent local immune 
response [21]. Furthermore, it is not known what effect the nature of the type of radiotherapy delivery 
or the particle used has on this interaction (e.g. open field radiotherapy versus intensity modulated 
radiotherapy or protons versus photons) and whether radiobiological effectiveness correlates to an 
increased tumour immune targeting in combination with checkpoint inhibitors. 
 
The ablative and highly targeted doses of stereotactic ablative radiotherapy (SABR) in combination 
with checkpoint inhibitors are highly attractive given the increased radiation induced inflammation 
seen with SABR and the reduced surrounding normal tissue toxicity. Key to any success of an 
immunotherapy and radiotherapy combination is the optimal scheduling of delivery of an 
immunomodulating agent with SABR. Recent preclinical data addressing scheduling has suggested 
that the anti-PD1 mAb must be given before and during the RT, but not after RT, to bring about long 
term tumour clearance [33]. Therefore administering the checkpoint inhibitor prior to the 
commencement of radiotherapy would appear to be a reasonable approach. Furthermore, the 
optimal duration of checkpoint inhibition following radiotherapy is not known, but it is likely that a 
minimum of 1-2 months will be necessary after completion of radiotherapy. Other potential areas of 
investigation the use of adjuvant immune modulation after the delivery of curative intent 
radiotherapy or chemoradiotherapy. If shown to be safe in combination with SABR or other 
radiotherapy delivery modalities perhaps adding immunotherapy to concurrent chemotherapy in 
stage III disease may be a consideration. Given the large RT fields generally used for stage III disease, 
this type of combination does however need to be approached with caution given the concerns about 
increased pulmonary toxicity from such combinations. Table 1 lists clinical studies of either Nivolumab 
or Pembrolizumab in combination with radiotherapy in the treatment of NSCLC listed on the Clinical 
Trials website [35-42]. 
 
Toxicity Considerations. 
One of ongoing concerns regarding immune checkpoint blockage is the risk of initiating autoimmune 
disease and in particular pneumonitis for lung cancer patients. Herbst et al report any grade 
pneumonitis rate of 4% and a grade 3 to grade 5 pneumonitis rate of 2% in those who received 
10mg/kg of Pembrolizumab [15]. Clearly delivering radiotherapy to normal tumour tissue in 
combination with immunotherapy may increase the risk of pneumonitis. Thus the design of potential 
phase 1 combination studies will need to consider this and consider more stringent dose constraints 
for normal lung tissue toxicity than would ordinarily be used. Other key immune mediated toxicities 
reported include hypo or hyperthyroidism, colitis, severe skin reactions, pancreatitis, myositis, adrenal 
insufficiency, hepatitis, hypophysitis and type 1 diabetes mellitus [15]. 
 
Beyond the immediate concern of immune mediated complications from such combinations described 
above, there is concern about delivery such radiotherapy and immunotherapy combinations in 
patients with advanced NSCLC, who often have multiple comorbidities precluding the use of cytotoxic 
systemic therapy in the first instance. In any early phase studies, when considering inclusion criteria, 
a judicious balance will have to be struck between ensuring safety of the study combination and the 
ensuring the study is representative of patients with advanced NSCLC.  It is recognised that novel trial 
designs will need to be considered to ensure safe and efficient recruitment [43]. 
 
Patient selection and stratification. 
There is currently intense investigation to investigate and develop immune biomarkers that predict 
the minority of patients who might benefit most from PD1-PD-L1 blockage. PD-L1 tumour expression 
has been used as an inclusion criteria for some of the mono-therapy studies in NSCLC [15]. However, 
any correlation between PD-L1 expression within the tumour, as measured by immunohistochemistry, 
has not been reproduced across the various studies and tumour subtypes. PD-1 expression of the 
immune effector cells populations in the tumour micro-environment is also of potential importance 
[44,45]. In the published studies of Nivolumab and Pembrolizumab in non-squamous NSCLC, there is 
a clear correlation between PD-1 expression and clinical response to treatment [15,17]. However this 
correlation is not seen in squamous cell NSCLC and in the recent study of Nivolumab in squamous 
NSCLC expression of the PD-1 ligand was neither prognostic nor predictive of benefit. [16]. Key to 
assessing PD-L1 expression is the method used and a recent study suggests that PD-L1 gene copy 
number may provide better correlation in selecting patients who are likely to respond to checkpoint 
inhibition [46]. However, it is not known if PD-L1 expression will correlate with clinical response in any 
checkpoint inhibitor and radiotherapy combination. Given the potential serious toxicities arising from 
the immune checkpoint inhibitors and comparatively low monotherapy response rates (19% seen in 
the second-line treatment of non-squamous NSCLC), patient selection for therapy will be paramount 
to ensuring an optimal combination with radiotherapy in patients with lung cancer [17].  
 
Challenges in assessing response. 
The key to assessing the utility of any RT and immunotherapy combination for patients with lung 
cancer is the assessment of response and clinical effectiveness. A potential challenge after either SABR 
or immunotherapy when given as single agent therapies is progressive disease as defined by RECIST 
criteria which is in fact pseudo-progression and appears indicative of immune effector cell infiltration 
into the tumour prior to eventual tumour response [47]. Pseudo-progression following SABR in the 
treatment of stage 1 lung cancer may be observed for up to 1 year after treatment, even when PET/CT 
is used to reassess the treated area and low grade FDG uptake may remain and increase in intensity 
for up to 1 year after treatment [48]. In a recent study of Pembrolizumab as monotherapy in the 
treatment of melanoma, RECIST 1.1 under-estimated the clinical response rates in up to 15% of 
patients [49-50]. Given that overall survival may be only robust endpoint at present for studies of 
immunotherapy and radiotherapy, there is an urgent need to update and revise tumour response 
criteria to best assess the real impact of radiotherapy and immunotherapy combinations making the 
best use of available cross-sectional imaging, biological imaging techniques and blood based 
biomarkers of response [51]. 
 
 
Conclusions. 
RT and immunotherapy combinations have an attractive underpinning complementary mechanism of 
action. The potential ability of radiotherapy and immunotherapy combinations to overcome tumour 
heterogeneity in lung cancer offers the hope of more effective and durable treatment responses. 
Studies are currently in set-up in the UK to investigate the combination of immunotherapy with 
radiotherapy in lung cancer and results from these studies are eagerly awaited. 
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